alidornase alfa
Pre-clinical- Indications
- Pulmonary sarcoidosis, Respiratory diseases
Company intelligence / Profile preview
SarcoMed USA
Texas, United Statessarcomedusa.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
SarcoMed USA’s lead program, SM001 (alidornase), is an inhaled DNase I therapy targeting chronic pulmonary inflammation in pulmonary sarcoidosis. The company completed a pre‑IND meeting with the FDA and received orphan drug status. Proof-of-concept studies are ongoing, including an open-label study using a biosimilar DNase1 in Kazakhstan. Additional indications under exploration include ARDS, idiopathic pulmonary fibrosis, and cystic fibrosis. An option exists on a no-alpha IL‑2 mutein drug for oncology indications with early clinical signals observed in Cuba.
- Therapeutic areas
- OncologyPulmonology
- Modalities
- ProteinRecombinant proteinSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Generium (biosimilar DNase1 supply)Roswell Park Cancer Center [collaboration on oncology asset]
Beyond the preview
Go deeper on SarcoMed USA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SarcoMed USA.